Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI.

@article{Mittra2013PreclinicalEO,
  title={Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI.},
  author={Erik Mittra and Hua Fan-Minogue and Frank I. Lin and Jason Raj Karamchandani and Venkataraman Sriram and May Sabai Han and Sanjiv Sam Gambhir},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 20},
  pages={5711-21}
}
PURPOSE Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize extensive preclinical work using this agent in a mouse brain orthotopic model of glioblastoma. EXPERIMENTAL DESIGN Sequential experiments were done using eight- to nine-week-old nude mice injected with 3 × 10(5) U87 MG (glioblastoma) cells into the brain. Evaluation of ficlatuzumab dose response for this brain tumor model and comparison of its response to ficlatuzumab and… CONTINUE READING
Highly Cited
This paper has 457 citations. REVIEW CITATIONS
6 Citations
12 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Complementary but distinct roles for MRI and 18 Ffl uoromi - sonidazole PET in the assessment of human glioblastomas

  • KR Swanson, G Chakraborty, CH Wang, R Rockne, HL Harpold, M Muzi
  • Neurosurgery
  • 2007

Similar Papers

Loading similar papers…